In an outsourcing landscape where 80% of first-time India programs face impairment-often costing $5–25M in delays, rework, and regulatory exposure-trust is not a soft value. It is a technical requirement.
Aventiq Bio acts as your Independent Technical Fiduciary.
We do not simply advise-we assume responsibility for governance decisions that protect your ROI, IP, and regulatory outcomes across India’s life sciences ecosystem.
We own no laboratories, manufacturing sites, or execution assets-and accept zero vendor commissions. Our loyalty is exclusively to your program’s success.
Our governance model is shaped by over two decades inside global CRO and CDMO environments-where we learned where programs actually fail, not where brochures say they succeed.
We maintain a live intelligence map of 150+ vetted Indian providers, ranked by talent density, quality culture, and regulatory behavior-not just stated capacity.
We enforce USFDA/EMA-aligned oversight from day one, ensuring India-sourced data is globally defensible and immune to “local interpretations” that trigger 9–18 month delays.
Our stewardship focuses where failure is most expensive: ADCs, HPAPIs, Cell & Gene Therapy, Vaccines, and Precision Medicine-programs that cannot tolerate generic oversight.
We stay physically engaged through the highest-risk phases-especially tech transfer and PPQ-until outcomes are stable, predictable, and inspection-ready.
We replace snapshot audits with permanent, AI-supported vigilance: early-warning dashboards, trend analysis, and unfiltered ground truth that protects your program long after contracts are signed.